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Clarithromycin attenuates IL-13–induced
periostin production in human lung
fibroblasts
Kosaku Komiya1,2,3,4, Shoichiro Ohta1, Kazuhiko Arima1, Masahiro Ogawa1, Shoichi Suzuki5, Yasutaka Mitamura1,
Satoshi Nunomura1, Yasuhiro Nanri1, Tomohito Yoshihara1, Atsushi Kawaguchi6, Jun-ichi Kadota3,
Bruce K. Rubin2 and Kenji Izuhara1*

Abstract
Background: Periostin is a biomarker indicating the presence of type 2 inflammation and submucosal fibrosis;
serum periostin levels have been associated with asthma severity. Macrolides have immunomodulatory effects
and are considered a potential therapy for patients with severe asthma. Therefore, we investigated whether
macrolides can also modulate pulmonary periostin production.
Methods: Using quantitative PCR and ELISA, we measured periostin production in human lung fibroblasts stimulated
by interleukin-13 (IL-13) in the presence of two 14-member–ring macrolides—clarithromycin or erythromycin—or a
16-member–ring macrolide, josamycin. Phosphorylation of signal transducers and activators of transcription 6 (STAT6),
downstream of IL-13 signaling, was evaluated by Western blotting. Changes in global gene expression profile induced
by IL-13 and/or clarithromycin were assessed by DNA microarray analysis.
Results: Clarithromycin and erythromycin, but not josamycin, inhibited IL-13–stimulated periostin production.
The inhibitory effects of clarithromycin were stronger than those of erythromycin. Clarithromycin significantly
attenuated STAT6 phosphorylation induced by IL-13. Global gene expression analyses demonstrated that IL-13
increased mRNA expression of 454 genes more than 4-fold, while decreasing its expression in 390 of these
genes (85.9%), mainly “extracellular,” “plasma membrane,” or “defense response” genes. On the other hand,
clarithromycin suppressed 9.8% of the genes in the absence of IL-13. Clarithromycin primarily attenuated the
gene expression of extracellular matrix protein, including periostin, especially after IL-13.
Conclusions: Clarithromycin suppressed IL-13–induced periostin production in human lung fibroblasts, in part
by inhibiting STAT6 phosphorylation. This suggests a novel mechanism of the immunomodulatory effect of
clarithromycin in asthmatic airway inflammation and fibrosis.
Keywords: Macrolide, Periostin, Asthma, Fibroblast, IL-13

Background
The immunomodulatory effects of macrolides were first
described in patients with diffuse panbronchiolitis in
1998 [1]. Macrolide immunomodulation was found to be
independent of antibiotic properties [2]. Their effects
include modulation (both increasing and decreasing) of
inflammatory cytokine production, decreasing airway
* Correspondence: kizuhara@cc.saga-u.ac.jp
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mucus hypersecretion, and blocking bacterial biofilm
formation and virulence factor production [2–5]. Macrolide therapy has been recommended for chronic obstructive pulmonary disease, cystic fibrosis, non-cystic
fibrosis bronchiectasis, and severe asthma [6–10]. In
patients with asthma, long-term macrolide therapy was
reported to improve airflow, quality of life, and airway
hypersensitiveness [11].
Periostin is an extracellular matrix protein that is associated with eosinophilic airway inflammation and the
severity of asthma. Periostin may enhance type 2
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inflammation and mucus hypersecretion [12–15]. Periostin is reported to be the most robust biomarker predicting the effectiveness of lebrikizumab, an anti-IL-13
antibody, for treating asthma [16–18]. As macrolides
also affect type 2-dominated inflammation in asthma,
we hypothesized that macrolide therapy may attenuate
IL-13 stimulated periostin production and inflammatory gene expression in human lung fibroblasts.

Methods
Cell culture
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Western blot analysis

Western blotting for STAT6 and phosphorylated STAT6
was performed as previously described [22]. MRC5 cells
were stimulated with the indicated concentration of IL13 at 37 °C for 1, 3, or 6 h. The cell lysates were applied
to SDS-PAGE and then electrophoretically transferred to
polyvinylidene difluoride membranes. Membranes were
incubated with either anti-phosphotyrosyl STAT6 antibody (Cell Signaling Technology, Beverly, MA, USA) or
anti-STAT6 Ab (Santa Cruz Biotechnology, Santa Cruz,
CA, USA), followed by incubation with secondary Abs
conjugated to horseradish peroxidase. The signals were
visualized with an enhanced chemiluminescence system
(Thermo Scientific, Waltham, MA, USA) and LAS-3000
(GE Healthcare, Pittsburg, PA, USA).

MRC5 cells, a human embryonic lung fibroblast cell line
(Riken BioResource Center, Tsukuba, Japan), were cultured with Dulbecco modified Eagle medium (SigmaAldrich, St. Louis, MO, USA) supplemented with 10%
fetal calf serum, 100 μg/mL streptomycin, and 100 U/mL
penicillin G. MRC5 cells (7 × 104 cells per well) were
placed in 24-well plates (Nunc, Roskilde, Denmark) and
cultured in 5% CO2 humidified atmosphere at 37 °C with
or without clarithromycin, erythromycin (Wako Pure
Chemical Industries, Osaka, Japan), josamycin (SigmaAldrich), ampicillin (Sigma-Aldrich), or dexamethasone
(Wako Pure Chemical Industries). Clarithromycin was
kindly supplied by Taisho Toyama Co., Ltd. (Tokyo,
Japan). Clarithromycin, erythromycin, josamycin, and
ampicillin were dissolved in ethanol (EtOH, Wako) to
therapeutic concentrations [19, 20]. Dexamethasone
was dissolved in EtOH to 100 nM [21]. The final concentration of EtOH added to cells was 0.5%. After 24 h
of culture, cells were stimulated by 50 ng/mL human
recombinant IL-13 (Peprotech, Rocky Hill, NJ, USA)
for 24 h. Cell viability was evaluated using WST-8 assay
(Cell Count Reagent SF, Nacalai Tesque, Kyoto, Japan).

MRC5 cells were stimulated with 50 ng/mL IL-13 for
24 h in the presence or absence of 5.0 × 10−5 M clarithromycin to evaluate not only the primary gene transcription but also the secondary gene expression caused
by the primary products. Total RNA with an RNA integrity number more than 7.0 was applied to Agilent
Expression Array (SurePrint G3 Human GE8x60K v2
Microarray, Takara Bio). The calculated relative signal
intensity values were presented on a heat map and subjected to MultiExperiment Viewer (MeV) v4.9 software
(Dana-Farber Cancer Institute, Boston, MA, USA). For
gene ontology analysis, the Database for Annotation
Visualization and Integrated Discovery (DAVID) tool
(National Cancer Institute, Frederick, MA, USA) was
used. This database includes the Gene Ontology Database (http://geneontology.org/).

Real-time PCR

Statistical analysis

Total RNA was extracted using RNAiso Plus (Takara
Bio, Otsu, Japan), and reverse-transcribed with ReverTra Ace (Toyobo, Osaka, Japan). Quantitative PCR reactions were performed with cDNA on a StepOnePlus
real-time PCR System (Life Technologies, Carlsbad,
CA, USA) using the Thunderbird SYBR qPCR mix
(Toyobo). PCR primers were as follows: periostin, forward primer, 5’-CTGCCAAACAAGTTATTGAGCTG
GC-3’, reverse primer, 5’-AATAATGTCCAGTCTCC
AGGTTG-3’ and glyceraldehyde-3-phosphate dehydrogenase (GAPDH), forward primer, 5’-TCACCACCAT
GGAGAAGGC-3’, reverse primer, 5’-GCTAAGCAG
TTGGTGGTGCA-3’. Threshold cycles of primer
probes were normalized by GAPDH Additional file 1.

Statistical analyses were performed using the Prism 5.0
software (GraphPad Software, La Jolla, CA, USA) and
the IBM SPSS statistics 21.0 software package (IBM
SPSS, Tokyo, Japan). Data were presented as mean ± SD.
The significance of differences was assessed using an unpaired Student’s t-test, except for the multiple comparisons of compounds, which were done using the ANOVA
plus post-test (Tukey). P values less than 0.05 were considered statistically significant.

ELISA

Periostin ELISA was performed using Periostin ELISA
Kit® (Shino-Test Corp., Tokyo, Japan) according to the
manufacturer's instruction.

DNA microarray analysis

Results
Clarithromycin inhibits periostin production in MRC5 cells

We first examined whether clarithromycin affects IL-13–
stimulated periostin production. We chose the concentrations of clarithromycin based on an earlier reference
showing the clarithromycin concentration in epithelial
lining fluid after taking clarithromycin [19]. IL-13 increased periostin expression approximately 10-fold
compared to control as reported previously [22] (Fig. 1).
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Fig. 1 Effects of clarithromycin on periostin production in MRC5 cells.
Periostin protein in supernatant measured by ELISA (a) or mRNA
by qPCR (b). Bars are depicted as mean ± SD. The same experiments
were performed twice for (A) and three times for (B). A representative
result of three individual experiments is shown. *; P < 0.05 compared
with IL-13 (50 ng/mL) plus EtOH (0.5%)

Clarithromycin significantly attenuated IL-13 stimulated periostin in a dose-dependent manner from 318 ±
19 ng/mL with no clarithromycin to 168 ± 18 ng/mL (at
5.0 × 10−5 M, P < 0.001). Cellular viability was not affected by clarithromycin at these concentrations (data
not shown). These results suggest that clarithromycin
inhibits periostin production in a dose-dependent manner in human fibroblasts.
Effects of macrolides, dexamethasone, and ampicillin on
periostin production

The immunomodulatory effects of macrolides have been
reported to be associated with the size of the macrolactam
ring; macrolides with 14- or 15-member rings exhibit
immunomodulatory properties, while these properties
are absent or attenuated in the 16-member–ring
macrolide antibiotics [2]. Clarithromycin, like erythromycin, is a 14-member–ring macrolide, while josamycin, has a 16-member ring. Clarithromycin robustly
inhibited periostin production at both 2.5 × 10−5 M (P
< 0.01) and 5.0 × 10−5 M (P < 0.001) (Fig. 2). Erythromycin inhibited IL-13–stimulated periostin production
more weakly than clarithromycin but significantly at
5.0 × 10−5 M (P < 0.01). However, josamycin had no effect

Fig. 2 Effects of erythromycin, josamycin, and ampicillin on periostin
production in MRC5 cells. MRC5 cells were cultured for 24 h in the
presence of the indicated concentrations of dexamethasone,
clarithromycin, erythromycin, josamycin, or ampicillin. Then the cells
were stimulated with 50 ng/mL IL-13 for 24 h. Periostin protein in
supernatant was measured by ELISA. The same experiments were
performed twice. Bars are depicted as mean ± SD. A representative
result of three individual experiments is shown. *; P < 0.05 compared
with IL-13 (50 ng/mL) plus EtOH (0.5%)

on periostin production (P = 0.3020), nor did ampicillin
(P = 0.6052). Dexamethasone, at a concentration of 10−7
M, also attenuated periostin production (P < 0.001). These
results suggest that clarithromycin and erythromycin, both
having 14-member rings, but not josamycin, with 16member ring, inhibit periostin production induced by IL13 in human lung fibroblasts.
Clarithromycin inhibits IL-13–induced STAT6
phosphorylation

IL-13 receptor activation signals through STAT6 phosphorylation [23]. Tanabe et al. reported that clarithromycin inhibits STAT6 phosphorylation in human bronchial
epithelial cells [20]. We hypothesized that STAT6 inhibition by clarithromycin would decrease IL-13–stimulated periostin expression in MRC5 fibroblasts. IL-13
induced STAT6 phosphorylation within 1 h, and this continued for more than 6 h (Fig. 3). Clarithromycin partially
attenuated STAT6 phosphorylation just 1 h after IL-13
exposure. These results suggest that clarithromycin attenuates periostin production induced by IL-13 at least partially by inhibiting STAT6 phosphorylation.
IL-13 and clarithromycin affect gene expression in
MRC5 cells

To examine the selectivity of the inhibitory effects by
clarithromycin on IL-13–induced expression, we analyzed
the changes in IL-13– and clarithromycin-dependent gene
expression. Global gene expression analysis showed that
IL-13 increased mRNA expression of 454 genes more than
4-fold. Of these 454 genes, clarithromycin exposure
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Fig. 3 Clarithromycin inhibits IL-13–stimulated STAT6 phosphorylation. MRC5 cells were stimulated by exposure to 50 ng/mL IL-13 in the presence or
absence of clarithromycin. Phosphorylated STAT6 in the cell lysates of MRC5 cells was analyzed by Western blot. Bars are depicted as mean ± SD. The
same experiments were performed three times; a representative result of three individual experiments is shown. **; P < 0.001 compared with
control, #; P < 0.05, ##; P < 0.001 compared with no clarithromycin, NS; not significant

attenuated expression of 390 (85.9%, Fig. 4a). The Gene
Ontology (GO) terminology provides uniform and consistent descriptions of genes and gene products (http://
geneontology.org/). We categorized the genes affected
by IL-13 and clarithromycin using GO terminology. IL-13
primarily increased mRNA in “extracellular,” “plasma
membrane,” or “defense response” genes, whereas clarithromycin suppressed these categories of genes, but had
no effect on “negative regulation of cell communication,”
“glycoprotein,” or “Golgi apparatus” genes (Fig. 4b and
Table 1). In GO terminology, periostin belongs to an
extracellular region gene. In the absence of IL-13 stimulation, clarithromycin suppressed 5758 of 58718 genes
(9.8%). The genes categorized as “extracellular region,”
“plasma membrane,” or “defense response,” which were
suppressed by clarithromycin in the presence of IL-13,
were only partially attenuated in the absence of IL-13: 9 of
56 genes (16.1%), 8 of 93 genes (8.6%), and 2 of 16 genes
(12.5%), respectively. These findings suggest that clarithromycin inhibits mainly “extracellular,” “plasma membrane,”
or “defense response” genes induced by IL-13 in which
periostin is involved.

Discussion
It has been consistently reported that macrolides with
14- and 15-member rings have much greater immunomodulatory effects than the 16-member ring macrolides
[2]. In this study, we showed that clarithromycin, a 14member–ring macrolide, showed the strongest inhibitory
effects on periostin expression induced by IL-13 among
the examined macrolides. Erythromycin, another 14member–ring macrolide, showed fewer inhibitory effects
while josamycin, a 16-member–ring macrolide, had no
such effects. The details of what causes these differences
in the inhibitory effects are thus far unclear; however,

our results are consistent with these reports in that clarithromycin had the greatest suppressive effect on IL-13–
induced periostin expression [2].
The Janus kinase (JAK)-STAT6 pathway is key to IL13 signaling [24]. We confirmed that clarithromycin
suppressed the phosphorylation of STAT6, but the ability of clarithromycin to attenuate periostin production
may not entirely be explained by inhibiting STAT6
phosphorylation. There are several reports that STAT6
inhibition stops most periostin expression in lung fibroblasts [25]. These data indicate that STAT6 is the exclusive regulator of periostin expression in lung fibroblasts.
On the other hand, we have recently demonstrated that
the periostin level is decreased in bronchial epithelial cells
by inhibitors against extracellular signal-regulated kinase
(ERK) and nuclear factor-kappa B (NF-κB) in addition to
STAT6, suggesting that in other cell types, the ERK and
NF-κB pathways are involved in periostin production [26].
Additionally, it has been reported that the ERK signaling
pathway positively regulates JAK1/STAT6 activity in T
cells [27]. On the other hand, macrolides are known to
decrease ERK and NF-κB signaling pathways [28].
Tanabe et al. reported that clarithromycin attenuates
these pathways and the JAK-STAT6 pathway [20].
Taken together, these results suggest that macrolides
may attenuate periostin production via the ERK or NFκB signaling pathways in addition to the JAK/STAT6
pathway. Clarithromycin may affect STAT6 signaling by
downregulating IL-13Rα1/IL-4Rα. We performed flow
cytometry to investigate the surface expression of the
cytokine receptors on MRC5 cells upon treatment with
clarithromycin (Additional file 2: Figure S1A). The
expression of IL-13Rα1 was not affected by clarithromycin. Although a statistically significant decrease of
IL-4Rα expression was observed, it seemed too slight to
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Fig. 4 Global gene expression analysis. a A hierarchical clustering using DNA microarray analysis of IL-13– and clarithromycin-dependent gene
expression changes in MRC5 cells. Genes whose expression were increased more than 4-fold by IL-13 without clarithromycin are displayed. The
rows represent genes; the experimental conditions are shown as columns. The color represents the expression level of the gene (Red represents
high expression, while green represents low expression). The dendrograms provide some qualitative means of assessing the similarity between
genes and between experimental conditions. Among IL-13–inducible genes, expression of 390 genes was decreased by 50% or more, 56 genes
were unaffected (0.5 to 1.5-fold), and expression of 8 genes was further increased by clarithromycin. b GO term decreased (a) or unchanged (b)
by clarithromycin among genes increased 4-fold by IL-13. Gene enrichment in each GO term was analyzed by Fisher’s exact test. P values for (a)
are extracellular region, 6.9E-04; plasma membrane, 1.6E-04; defense response, 6.1E-04; epidermis development, 1.3E-03; TNFR, 2.3E-02; positive
regulation of immune system process, 4.5E-03; positive regulation of multicellular organismal process; 5.1E-03; and regulation of protein kinase
cascade, 5.6E-03. P values for (b) are negative regulation of cell communication, 9.4E-03; glycoprotein, 5.6E-03; Golgi apparatus part, 2.1E-02;
chemotaxis, 4.0E-02; signal, 7.0E-02; and regulation of phosphorylation, 2.4E-01

explain the considerable attenuation of the periostin
production by clarithromycin. To confirm the expression of these receptors at the transcriptional level, we
also performed quantitative PCR, finding no suppressive effect by clarithromycin (Additional file 2: Figure
S1B). Consequently, we conclude that the inhibition of
the STAT6 signaling by clarithromycin is not mainly due
to downregulation of the IL-13Rα1/IL-4Rα expression.
We found that clarithromycin showed significantly
suppressive effects on IL-13–inducble genes (Fig. 4).
These specific genes, whose expression was attenuated
by clarithromycin after IL-13 exposure, were dominantly
categorized as “extracellular region,” “plasma membrane,” and “defense response” genes, among which
asthma-related CD40, NOS2, and CXCL1 (Table 1A)
were included. The improvement of asthma symptoms
by clarithromycin may be attributed to the downregulation of these genes in addition to periostin. In contrast to
suppression of genes activated by IL-13, constitutive expression of these genes was less affected by clarithromycin.

Macrolides are classified as ‘immunomodulators’ and decrease hyperinflammation without impairing the normal
immune system against infection, as differentiated from
immunosuppressive agents such as glucocorticosteroids
[2]. The detailed mechanism of how macrolides select for
suppressive genes still remains unclear; however, our
present finding that clarithromycin selectively suppresses
IL-13–inducible genes including periostin may shed light
on this mechanism. Extracellular matrix proteins constitute a positive feedback loop in lung fibrosis [23, 29].
Masuoka et al. showed that type 2 cytokines stimulated
fibroblasts to produce periostin, interacting with αv integrin, a functional periostin receptor, on keratinocytes [23].
Inhibition of periostin or αv integrin prevented the development or progression of allergen-induced skin inflammations, including fibrosis. Macrolides are reported to have
anti-fibrotic effects [30], implying that they may attenuate
fibrosis by modulating extracellular matrix proteins.
Serum periostin levels are significantly increased in asthmatic patients [12]. The role of periostin on fibrogenesis

Komiya et al. Respiratory Research (2017) 18:37
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Table 1 Representative genes that were increased more than
4-fold by IL-13 according to the global gene expression analysis
(see Figure 4.)
(A) Cluster

Table 1 Representative genes that were increased more than
4-fold by IL-13 according to the global gene expression analysis
(see Figure 4.) (Continued)

Gene Symbol

CAM effect

Unassigned

SPDYE8P

0.1491

Extracellular

PLXDC1

0.0342

Defense response

CD19

0.1667

Extracellular

SLIT2

0.4594

Unassigned

LOC100129675

0.1696

Extracellular

POSTN

0.4979

Unassigned

LOC102724783

0.1880

Extracellular

WNT10B

0.4239

Plasma membrane

SYT8

0.2078

Plasma membrane

CACNA1D

0.0807

Centriole

SASS6

0.2079

Plasma membrane

RTP1

0.1379

Plasma membrane

APC

0.2138

Plasma membrane

SYT8

0.2078

Plasma membrane

RALGPS1

0.2754

Plasma membrane

APC

0.2138

Defense response

CD40

0.0131

Defense response

NOS2

0.3132

Defense response

CD19

0.1667

Defense response

IFNL1

0.0426

Defense response

CXCL1

0.2197

(B) Cluster

Gene Symbol

CAM effect

Glycoprotein

IL17RA

0.9564

Glycoprotein

ST8SIA1

0.6773

Glycoprotein

SPINT2

0.8788

Glycoprotein

IL1RL1

0.7990

Glycoprotein

SULF1

0.5449

Glycoprotein

APLNR

1.0210

Glycoprotein

HS3ST1

0.9854

Chemotaxis

CCL26

1.2418

Chemotaxis

IL6

0.8210

Chemotaxis

PTGDR2

0.7217

Signal regulator

SOCS1

1.1385

Signal regulator

CISH

0.8930

Gene Symbol

IL-13 effect

(C) Cluster
Chemotaxis

CCL26

35.6732

Glycoprotein

HS3ST1

12.2410

Glycoprotein

ST8SIA1

10.7933

Chemotaxis

IL6

10.1221

Signal regulator

CISH

8.9751

Chemotaxis

PTGDR2

7.2666

Unassigned

LINC00971

7.2156

Signal regulator

SOCS1

6.3270

Glycoprotein

IL17RA

5.9221

Extracellular

SLIT2

5.7987

(D) Cluster

Gene Symbol

CAM effect

Plasma membrane

SLC22A20

0.1237

Unassigned

XLOC_006850

0.1403

Unassigned

XLOC_014512

0.1420

(A) Genes suppressed by 50% or more by clarithromycin. (B) Genes not affected by
clarithromycin. The clarithromycin (CAM) effect denotes the ratio of signal intensities
obtained by clarithromycin treatment compared with no treatment. (C) The ten
top-ranked ten genes induced by IL-13. (D) The ten top-ranked genes
downregulated by clarithromycin in the presence of IL-13. The clarithromycin
(CAM) effect denotes the ratio of signal intensities obtained by clarithromycin
treatment compared with no treatment. The IL-13 effect denotes the ratio of
signal intensities obtained by IL-13 stimulation compared with no stimulation

has been explored, showing that epithelial cell-derived
periostin increased secretion of type 1 collagen from airway fibroblasts [14]. Attenuation of periostin production
by macrolides may decrease both asthmatic airway inflammation and fibrosis.
This study has a certain limitation. We selected the
concentration of clarithromycin (5.0 × 10−5 M) based on
a previous report showing the clarithromycin concentration in epithelial lining fluid after taking clarithromycin
[19]. Our study and most of the studies assessing the
effects of macrolides used the unified concentrations
for each drug when comparing the immunomodulatory
effects among macrolides with different types of rings
[4, 5]. We did not evaluate whether these drugs at the
same concentrations were equally efficacious with other
assay such as bactericidal activity. Thus, the results do
not necessarily prove actual intrinsic differences in the
inhibitory efficacy of these drugs.

Conclusions
Clarithromycin suppressed IL-13–induced periostin production in human lung fibroblasts, in part through inhibition of STAT6 phosphorylation. This suggests a novel
mechanism of the immunomodulatory effect of clarithromycin in asthmatic airway inflammation and fibrosis.
Additional files
Additional file 1: Figure S1. Expression of IL-4Rα and IL-13Rα1 in MRC5
cells. (A) Cell surface expression of IL-4Rα and IL-13Rα1 was assessed by flow
cytometry. Mean fluorescent intensities (MFI) of the stained cells are shown.
(B) Expression of mRNA of the indicated genes was assessed by quantitative
RT-PCR. Fold changes over vehicle are shown. Black columns, clarithromycin
(CAM); gray columns, vehicle. Statistical analyses were performed using
Bonferroni’s multiple comparison test. P values of 0.05 or less were regarded
significant. NS, not significant; MFI, mean fluorescent intensity. (PPT 121 kb)
Additional file 2: Materials and Methods. (DOCX 21 kb)
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